PPAR Research / 2008 / Article / Tab 1

Review Article

TZDs and Bone: A Review of the Recent Clinical Evidence

Table 1

Fracture rates comparing rosiglitazone with metformin or glyburide in ADOPT study. Table adapted from a Letter to Health Care Providers issued by GSK [4].

RosiglitazoneMetformin or glyburideRelative rate (95% CI)

Total followup (P-Y)2187.203578.80

Fracture site Rate/100PY Rate/100PYRR(95% CI)

Lower limb*361.65260.732.27(1.33, 3.91)
Hip20.0920.061.64(0.12, 22.57)
Foot221.01110.313.27(1.52, 7.47)
Upper limb221.01190.531.89(0.98, 3.70)
Hand80.3750.142.62(0.76, 10.17)
Spine10.0520.060.82(0.01, 15.72)
Other50.2380.221.02(0.26, 3.55)

All fractures642.93551.541.90(1.31, 2.78)

Total followup (P-Y)2766.705570.40

Rate/100PY Rate/100PYRR(95% CI)
Total participants with any fracture321.16571.021.13(0.71, 1.77)

* Hip, foot, ankle, femur, fibula, lower limb (general), patella, tibia. Hand, humerus, clavicle, forearm, radius, upper limb (general), wrist. Cannot estimate. No events in the comparison group.Reprinted with permission from [5]

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.